12:00 AM
 | 
Jul 30, 2007
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 2Q07 EPS est 2Q07 EPS actual Outcome Growth from 2Q06 7/27 cls Wk chg % chg Mcap chg 7/27 Mcap
Affymetrix (AFFX) $0.03 $0.05 Beat by $0.02 NA $25.14 -$0.19 -1% -$13.0 $1,715.7
AFFX posted a loss per share of $0.15 in 2Q06. Second quarter revenues were up 10% to $88.3M from $80.1M in 2Q06. The microarray company continues to expect full year revenues of $365-$385M.
Alexion (ALXN) -$1.03 -$0.75 Beat by $0.28 NA $58.62 $8.12 16% $292.6 $2,112.1
ALXN reported a loss per share of $1.06 in the same period last year. 2Q07 revenues were $9.8M, which beat the Street's $4M estimate. The revenues came from Soliris, the company's paroxysmal nocturnal hemoglobinuria (PNH) drug, which was approved by FDA in March and by the EC last month.
Amgen (AMGN) $1.06 $1.12 Beat by $0.06 7% $55.62 -$0.56 -1% -$653.5 $64,908.5
Sales of Aranesp for anemia were $949M, down 10% from $1.1B in 2Q06 and down 7% from $1B in 1Q07. The decrease was driven by label and reimbursement changes in the U.S. for all erythropoiesis-stimulating agents (ESAs). First-generation EPO drug Epogen had 2Q07 sales of $624M, up 2% from $613M in the same period last year but flat vs. $625M in 1Q07. In addition to the ESAs, AMGN's Vectibix also posted a sequential decline in sales. The anti-EGFR antibody for colorectal cancer was launched last October and posted 2Q07 sales of $45M, down 12% from $51M in 1Q07. AMGN said the decrease was driven by the negative Phase IIIb PACCE data released in March and a decline in the EGFR class growth. Sales of neutropenia products Neupogen and Neulasta were $1.04B, up 4% from $1B in 2Q06. Second quarter sales of Enbrel, which is marketed for rheumatoid arthritis (RA) and other inflammatory indications, were up 14% to $823M in North America. Wyeth (WYE) has exclusive rights to Enbrel outside North America (see "EPO Unloading," A9).
Amylin (AMLN) -$0.34 -$0.34

Read the full 1843 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >